SUMMARYThe acute oral and parenteral LD-5o of beta-cyclodextrin was established on rats, mice and aog~.The long term toxicity studies were performed on rats and 2.~.dogs following the two weeks dose finding studies given the test substance by oral route. All of the animals were autopsied and the tissue samples were examined histopathologically in both experiments. Investigation of the effect of beta-cyclodextrin on hepatic drug metabolizing enzyme system of rats did not show any alteration in the activity.According to our results the beta-cyclodextrin given orally to rats and dogs did not cause any side effect during the long term toxicity stUdies.
The toxic side-effects and anti-inflammatory activity of combination treatment of Sprague-Dawley rats with indomethacin and Probon, a new type of analgesic, were investigated. Following four weeks of treatment with a combination of these two drugs, the characteristic gastrointestinal side-effect of indomethacin was markedly reduced. Mortality resulting from administration of the drug combination was significantly lower than that resulting from indomethacin treatment alone. The reduced toxicity of indomethacin in combination with Probon is probably due to a change in metabolism produced by the hepatic microsomal enzyme inducer, Probon. The anti-inflammatory effect was also investigated using a contact thermographic method following one, three or seven days pretreatment. The advantage of this combination is that, using a higher dose of indomethacin in combination with the minor analgesic, we could achieve a more reliable anti-inflammatory effect together with a pain-killing action.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.